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Abstract
Background: Although gangliocytic paraganglioma (GP) has generally been regarded as a neuroendocrine tumor,
its origin remains unclear. We therefore aimed to investigate the details of this disease by carefully analyzing and
extracting common features of the disease as presented in selected publications.
Methods: We searched for English and Japanese cases of GP using the PubMed and IgakuChuoZasshi databases
on August 2010. We then extracted and sampled raw data from the selected publications and performed
appropriate statistical analyses. Additionally, we evaluated the expression of hormone receptors based on our
previously reported case.
Results: 192 patients with GP were retrieved from the databases. Patient ages ranged from 15 y to 84 y (mean:
52.3 y). The gender ratio was 114:76 (male to female, 2 not reported). Maximum diameter of the tumors ranged
from 5.5 mm to 100 mm (mean: 25.0 mm). The duodenum (90.1%, 173/192) was found to be the most common
site of the disease. In 173 patients with duodenal GP, gastrointestinal bleeding (45.1%, 78/173) was found to be the
most common symptom of the disease, followed by abdominal pain (42.8%, 74/173), and anemia (14.5%, 25/173).
Rate of lymph node metastasis was 6.9% (12/173). Our statistical analysis indicated that significant differences were
found for gender between GP within the submucosal layer and exceeding the submucosal layer. Furthermore, our
immunohistochemical evaluation showed that both epithelioid and pancreatic islet cells showed positive reactivity
for progesterone receptors.
Conclusions: Our literature survey revealed that there were many more cases of GP exceeding the submucosal
layer than were expected. Meanwhile, our statistical analyses and immunohistochemical evaluation supported the
following two hypotheses. First, vertical growth of GP might be affected by progesterone exposure. Second, the
origin of GP might be pancreatic islet cells. However, it is strongly suspected that our data have been affected by
publication bias and to confirm these hypotheses, further investigation is required.
Background
Gangliocytic paraganglioma (GP) was first reported as
ganglioneuroma by Dahl et al. in 1957 [1] and Kepes et
al. named this disease entity as GP in 1971 [2].
Although GP has generally been regarded as a neuroen-
docrine tumor, some authors have reported that GP is a
hamartoma developing in misplaced embryonic pancrea-
tic tissue [3-5]. Despite these investigations, the origin
of GP remains unclear. However, a few cases of
GP showing lymph node metastasis are well known
[Table 1], and we previously reported such a case [6].
That case prompted us to survey publications of GP to
investigate mechanisms for GP. In the present study, we
searched literature databases and selected publications
of GP in English and Japanese from 1957 to the early
trimester of 2010 in order to investigate details of the
disease.
Few studies reported the epidemiology, pathology, and
clinical characteristics of the disease. We then evaluated
the details of the disease by carefully analyzing and
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in these selected publications.
Methods
We searched English and Japanese cases of GP pub-
lished from 1957 to the early trimester of 2010 using
the PubMed http://www.ncbi.nlm.nih.gov/pubmed/ and
IgakuChuoZasshi http://www.jamas.or.jp/ databases on
August 2010 by conducting a search of “gangliocytic
paraganglioma” with case report options as an additional
tool. As a result, 4574 English and 27 Japanese publica-
tions were retrieved.
We checked the abstracts and 73 English and 24 Japa-
nese (total 97) publications were regarded as cases of
GP and 4504 publications were excluded.
Since this disease entity has been reported under other
names, prior to Kepes et al. naming it as a GP [2], such
as “ganglioneuroma”, “non-chromaffin paraganglioma”,
and “paraganglioneuroma”, we checked the references of
97 selected publications.
Finally, we added 8 publications as GP reports because
they met the following criteria:
1. The characteristic three components could be con-
firmed in the manuscript or a figure.
2. The paper was cited in other publications as a GP
report.
These 105 publications contained reports on 192
patients with GP. In the present study, we conducted a
non-systematic literature review using 173 patients with
duodenal GP.
We extracted and sampled raw data from the selected
publications, such as clinical findings (age, sex, clinical
symptoms, operation method, and outcome), histo-
pathological findings (site, maximum diameter of the
tumor, diagnostic rate from biopsy before operation, the
depth of the tumor invasion, and with or without lymph
node metastasis), and immunohistochemical findings.
In addition, we performed appropriate statistical ana-
lyses using the extracted data. Statistical analyses were
performed using the non-parametric Mann-Whitney U
test or Chi-square test.
Differences were considered significant at P < 0.05.
Additionally, we evaluated gender differences based on
the results of our statistical analyses. Moreover, we eval-
uated the expression of hormone receptors in relation
to estrogen and progesterone based on our previously
reported case [6].
Finally, we declare that our study may be affected by
publication bias because it comprises a cumulating case
series.
Result
Overall findings
192 patients with GP were retrieved from the PubMed
and IgakuChuoZasshi databases. Patient ages ranged
from 15 y to 84 y (mean: 52.3 y). The gender ratio was
Table 1 Duodenal gangliocytic paraganglioma with lymph node metastasis
Reference Year Age
(years)
Sex Chief Clinical presentation Size
(mm)
Operation Follow up (months)
Buchler et al.
[50].
1985 50 Male Gastrointestinal bleeding 30 Surgical intervention NED 20
Inai et al. [51]. 1989 17 Male Hematoemesis 20 PD NED 32
Hashimoto et al.
[52].
1992 47 Male Incidental findings 65 PD NED 14
Takabayashi et al.
[53].
1993 63 Female Abdominal pain 32 PPPD NED 24
Dookhan et al.
[24].
1993 41 Male Abdominal pain 25 Additional surgical
intervention
Recurrence 11 years after first surgical
intervention
Sundararajan et
al. [54].
2003 67 Female Incidental findings 50 PD NED 9
Bucher et al. [55]. 2004 31 Female Anemia, subclinical jaundice 30 PPPD NED 44
Wong et al. [25]. 2005 49 Female Melena 14 PPPD NED 12
Witkiewicz et al.
[36].
2007 38 Female Abdominal pain 15 PPPD NR
Mann et al. [56]. 2009 17 Female Abdominal pain, vomiting,
weight loss
NR PPPD NR
Okubo et al. [6] 2010 61 Male Epigastralgia, tarry stool 30 PPPD NED 6
Saito et al. [46]. 2010 28 Male Gastrointestinal bleeding,
anemia
17 PD NED 12
NR: not reported, PD: pancreatoduodenectomy, PPPD: pylorus-preserving pancreaticoduodenectomy
NED: no evidence of disease
There were twelve cases of gangliocytic paraganglioma with lymph node metastasis.
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meter of the tumors ranged from 5.5 mm to 100 mm
(mean: 25.0 mm). The duodenum (90.1%, 173/192) was
found to be the most common site of the disease, fol-
lowed by the low-level spinal cord (2.1%, 4/192) [7-10],
respiratory system (2.1%, 4/192) [11-14], jejunum (1.6%,
3/192) [5,15,16], and esophagus (1.0%, 2/192) [17,18].
There were individual cases involving the stomach [5],
appendix [19], retromediastinum [20], pancreas [21],
and mature teratoma [22] (constituent of the lesion), as
w e l la sac a s eo fd o u b l ef o c u si nt h ed u o d e n u ma n d
pancreas [23] (0.5%, 1/192, respectively). In accordance
with these findings, the present study focuses on the
duodenal lesion, which represents the site for the over-
whelming majority of cases of the disease.
Clinical findings
173 patients with duodenal GP were retrieved from the
PubMed and IgakuChuoZasshi databases. Patient ages
ranged from 15 y to 84 y (mean: 52.6 y). The gender
ratio was 102:69 (2 not reported).
Gastrointestinal bleeding (45.1%, 78/173) was found to
be the most common symptom of the disease among the
symptoms reported in the papers, followed by abdominal
pain (42.8%, 74/173), and anemia (14.5%, 25/173). In
contrast, biliary obstruction was extremely rare (4.6%, 8/
173). The follow-up period ranged from 12 months to 96
months, and no death from GP was reported. With the
exception of a patient that had part of a previous tumor
at the initial operation [24], no recurrence has been
reported. There is only one report of a patient who
underwent radiotherapy after surgical intervention [25].
15 patients underwent an endoscopic procedure for
removal [26-40], and one patient required additional sur-
gical intervention due to the presence of a tumor residue
following her first endoscopic intervention [36].
Histopathological findings
Histopathological findings from forceps biopsies per-
formed prior to surgical intervention were described in
35 patients. Among these cases, 4 patients were cor-
rectly diagnosed as GP, 24 patients did not show evi-
dence of tumor cells (specimens did not contain tumor
cells), and 7 patients were diagnosed or suspected of
having a different neuroendocrine tumor (3 carcinoid
tumors, 2 paragangliomas, 1 ganglioneuroma, and 1 case
involving atypical cells).
The maximum diameter of the tumors ranged from
5.5 mm to 100 mm (mean: 24.2 mm). The depth of the
tumor invasion was described in 108 patients, compris-
ing 42 patients with submucosal invasion, 62 with mus-
cularis propria invasion, and 4 with connective tissue
beneath the muscularis propria. In summary, 42 patients
had GP within the submucosal layer and 66 patients
had GP exceeding the submucosal layer. Moreover, 12
of these patients showed lymph node metastasis that
involved one submucosal lesion [Table 1].
Immunohistochemical findings
Representative findings for each of the three characteris-
tic components of tumor cells are as follows. In epithe-
lioid cells, neuron specific enolase (NSE) showed the
highest positive rate (93.9%, 77/82), followed by synap-
tophysin (90.0%, 36/40), pancreatic polypeptide (PP;
89.7%, 70/78), somatostatin (81.8%, 63/77), chromogra-
nin-A (67.4%, 60/89), cytokeratins (48.3%, 28/58), and
serotonin (22.0%, 13/59).
In spindle-shaped cells, S-100 protein showed the
highest positive rate (94.2%, 98/104), followed by NSE
(84.0%, 63/75), and synaptophysin (64.7%, 22/34).
In ganglion-like cells, synaptophysin showed the high-
est positive rate (94.3%, 33/35), followed by NSE (84.0%,
63/75), somatostatin (44.1%, 30/68), and PP (22.2%, 16/
72). Immunohistochemical findings are summarized in
Table 2.
Comparative analysis of clinicopathological findings
To determine significant factors associated with the pro-
gression of the tumor, the following comparative ana-
lyses were carried out.
When we employed evidence of metastasis as an indi-
cator of progression, a significant difference was found
only for the ages of patients among the clinicopathologi-
cal findings concerning those with and without lymph
node metastasis (Mann-Whitney U test: p = 0.01), and
patients with metastasis were significantly younger than
those without metastasis. In contrast, no significant dif-
ferences were found in the maximum diameter of the
tumors or gender when comparing patients with and
without lymph node metastasis (Mann-Whitney U test:
p = 0.10 or Chi-square test: p = 0.55, respectively).
These results are summarized in Table 3.
Furthermore, comparisons of clinicopathological find-
ings revealed significant differences for both gender and
the rate of lymph node metastasis in patients when
comparing GP within the submucosal layer and exceed-
ing the submucosal layer (Chi-square test: p = 0.02,
0.03, respectively). Namely, patients having GP exceed-
ing the submucosal layer were predominantly female
and showed a higher rate of lymph node metastasis.
These results are summarized in Table 4.
However, no significant differences were found for the
maximum diameter of the tumor or the age of a patient
between males and females. In addition, Spearman’s
rank correlation coefficient was calculated to assess any
potential relationship between the maximum diameter
of the tumors and ages of patients, but no significant
relationships were found.
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Since the results mentioned above suggested that progres-
sion of the tumor has some relationship with sex hormone
activities, we evaluated the expression of hormone recep-
tors in relation to estrogen and progesterone based on our
previously reported case of GP. As a result, epithelioid
cells in both primary and metastatic foci showed strongly
positive reactivity for progesterone receptors and negative
reactivity for estrogen receptors [Figure 1]. In addition,
normal pancreatic islet cells showed strongly positive reac-
tivity for progesterone receptors and weakly positive reac-
tivity for estrogen receptors [Figure 1].
Discussion
We collected as many publications written in English or
Japanese involving GP and examined them to extract
characteristic features of the tumor as presented in clini-
cal and histopathological findings.
We focused on determining the significant factors
associated with the progression of the tumor. Here we
discuss the clinical, histopathological, and immunohisto-
chemical findings in reference to matters that emerged
from our research.
In the present study, we found gastrointestinal bleed-
ing as the most common symptom, followed by
abdominal pain. This fact has been previously accepted
and our data confirm it. All patients without autopsies
and having clinically incidental focus had surgical
interventions, including 15 patients with endoscopic
intervention. Indeed, one patient required additional
surgical intervention due to a residue of the tumor at
her first endoscopic procedure [36], while other
patients showed a good outcome without recurrence
or metastasis. Furthermore, there was no record of a
patient dying from GP, and patients with this tumor,
therefore, have an extremely good prognosis. However,
one patient has been reported as showing a recurrence
due to a residue of a previous tumor at his initial sur-
gical intervention [24]. Accordingly, we emphasize the
importance of both a histopathological assessment of
extensive tumor components at the surgical margin
Table 2 Immunohistochemical findings for each of the three characteristic components of the tumor
Epithelioid cells Spindle-shaped cells Ganglion-like cells
S-100 3.8% (4/104) 94.2% (98/104) 9.3% (9/97)
Synaptophysin 90.0% (36/40) 64.7% (22/34) 94.3% (33/35)
Chromogranin A 67.4% (60/89) 7.2% (6/83) 15.4% (12/78)
Neuron specific enolase 93.9% (77/82) 84.0% (63/75) 84.0% (63/75)
Cytokeratins 48.3% (28/58) 4.0% (2/50) 3.9% (2/51)
Vimentin 14.3% (1/7) 50.0% (2/4) 0.0% (0/6)
Neuron fiber 20.9% (14/67) 66.7% (44/66) 24.6% (16/65)
Pancreatic polypeptide 89.7% (70/78) 0.0% (0/72) 22.2% (16/72)
Somatostatin 81.8% (63/77) 8.7% (6/69) 44.1% (30/68)
Serotonin 22.0% (13/59) 0.0% (0/55) 16.7% (9/54)
Vasoactive intestinal polypeptide 12.1% (4/33) 12.9% (4/31) 9.7% (3/31)
Glucagon 6.4% (3/47) 0.0% (0/44) 2.4% (1/42)
Gastrin 5.9% (4/68) 0.0% (0/64) 0.0% (0/63)
Insulin 2.2% (1/46) 0.0% (0/41) 0.0% (0/42)
Positive or negative findings from immunohistochemistry in 173 extracted duodenal gangliocytic paraganglioma are summarized.
Table 3 Comparison of clinicopathological findings between patients with and without lymph node metastasis
Patients with lymph node
metastasis
Patients without lymph node
metastasis
Statistical analysis
Number of patients 12 161
Age (years) 17 to 67 (mean: 43.5) 15 to 84 (mean: 53.4) Significant difference was found
(Mann-Whitney U test: p = 0.01)
Maximum diameter of the tumor
(mm)
5.5 to 65 (mean: 29.8) 10 to 100 (mean: 23.5) No significant difference was
found
(Mann-Whitney U test: p = 0.10)
Gender (male to female) 6:6 96:63 (2 not reported) No significant difference was
found
(Chi-square test: p = 0.55)
A significant difference was found for the ages of patients with and without lymph node metastasis (Mann-Whitney U test: p = 0.01), and patients with lymph
node metastasis were significantly younger than those without lymph node metastasis. In contrast, no significant differences were found for maximum diameter
of the tumor or gender in patients with and without lymph node metastasis (Mann-Whitney U test: p = 0.10 or Chi-square test: p = 0.55, respectively).
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or metastasis after the operation.
Although one patient received irradiation after surgical
intervention [25], we maintain that patients without
residual tumor require no adjuvant therapy because no
recurrence or metastasis has been reported in such
patients. By contrast, it is still unclear whether a residual
tumor can be controlled by irradiation or chemotherapy
alone without surgical intervention.
The immunohistochemical findings on the tumors
need consideration since the identification of three cel-
lular components are essential for diagnosis. Epithe-
lioid and ganglion-like cells showed a high positive
rate for several kinds of immunohistochemical
neuroendocrine markers, such as synaptophysin, chro-
mogranin A, and NSE. In addition, epithelioid cells
showed a high positive rate for PP. In contrast, spin-
dle-shaped cells had the highest positive rate for S-100.
These results are consistent with other previous publi-
cations. Furthermore, positive rates for each hormone,
such as somatostatin, serotonin, gastrin, glucagon, and
insulin in epithelioid cells, were significantly different
and the meaning of this finding is worth investigating.
However, these extracted immunohistochemical find-
ings should be regarded as hints or suggestions
because it is thought that results involving negative
data have not been described in previous publications.
In fact, our previous case report did not describe the
Table 4 Comparison of clinicopathological findings between GP within and exceeding the submucosal layer
Gangliocytic paraganglioma within
the submucosal layer
Gangliocytic paraganglioma
exceeding the submucosal layer
Statistical analysis
Number of patients 42 66
Age (years) 28 to 84 (mean: 54.1) 15 to 73 (mean: 50.0) No significant difference was found
(Mann-Whitney U test: p = 0.23)
Maximum diameter of
the tumor (mm)
5.5 to 65 (mean: 21.7) 10 to 100 (mean: 26.8) No significant difference was found
(Mann-Whitney U test: p = 0.18)
Gender (male to
female)
29:13 30:36 Significant difference was found
(Chi-square test: p = 0.02)
Rate of lymph node
metastasis
2.4% (1/42) 16.7% (11/66) Significant difference was found
(Chi-square test: p = 0.03)
Significant differences were found for gender and the rate of lymph node metastasis between patients with GP within the submucosal layer and exceeding the
submucosal layer (Chi-square test: p = 0.02, 0.03, respectively).
Figure 1 Photomicrographs showing immunohistochemistry for estrogen and progesterone receptors. (A and B) Epithelioid cells in both
primary and metastatic foci were negative for estrogen receptors (× 400). (C) Pancreatic islet cells showed a weakly positive reactivity for
estrogen receptos (× 400). (D and E) Epithelioid cells in both primary and metastatic foci showed a strongly positive reactivity for progesterone
receptors (× 400). (F) Pancreatic islet cells showed a strongly positive reactivity for progesterone receptors (× 400).
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according to negative reactivity.
Incidentally, we previously tried to establish the
immunohistochemical prognostic indicators of GP using
bcl-2, p53, and Ki-67, which are acceptable prognostic
indicators in several kinds of neuroendocrine tumors
[41-44]. However, all of these indicators showed a nega-
tive reactivity.
Unfortunately, there were no other cases of GP that
included an immunohistochemical evaluation using bcl-
2 and p53, and the value of these factors as prognostic
indicators of GP remains unclear.
In contrast, two cases without lymph node metastasis
were described with the Ki-67 labeling index in GP
[45,46]. However, both showed extremely low Ki-67
labeling index values. Therefore, we suggest that immu-
nohistochemical evaluation using Ki-67 may have a lim-
ited prognostic value in GP.
Finally, we gained insight into the progression of GP
tumors and related factors. It has been accepted that GP
usually arises from the submucosal or muscular layer,
which may make the diagnosis difficult using a forceps
biopsy prior to surgical intervention. In fact, we revealed
that the diagnostic rate by biopsy before surgical inter-
vention was only 11.4% (4/35). In addition, we showed
that many more cases of GP exceeding the submucosal
layer were reported (61.1%, 66/108) than expected, and
GP exceeding the submucosal layer is a risk factor for
lymph node metastasis. These facts emphasize the
importance of imaging examinations prior to surgical
interventions.
It is interesting to note that significant differences
were found for gender between GP within the submuco-
sal layer and exceeding the submucosal layer. On the
basis of our investigation, a hypothesis emerged that
asserted no significant relationship for gender and that
female gender induces vertical growth of the tumor. To
confirm part of our hypothesis, we focused on female-
specific factors and initially evaluated tumor cells immu-
nohistochemically using anti-estrogen and progesterone
receptor antibodies. As a result, our immunohistochem-
ical evaluation revealed that epithelioid cells showed
positive reactivity for the progesterone receptor.
Furthermore, some investigators reported that proges-
terone regulates neural differentiation [47,48]. These
facts suggest that the vertical growth of GP might be
affected by progesterone exposure.
Additionally, it is interesting to note that normal
pancreatic islet cells also showed positive reactivity for
the progesterone receptor. It has been reported that
normal pancreatic islet cells and pancreatic neuroen-
docrine tumors showed positive reactivity for the pro-
gesterone receptor [49], and our literature survey
demonstrated that epithelioid cells showed a high
positive rate for PP (89.7%, 70/78) immunohistochemi-
cally. These facts indicate the relationship between GP
and pancreatic islet cells. However, immunohisto-
chemical evaluation for estrogen receptors differs
between epithelioid cells and normal pancreatic islet
cells, and our immunohistochemical evaluation was
based on only one patient. Furthermore, it is strongly
suspected that our data have been affected by publica-
tion bias.
To confirm these hypotheses, further investigation is
required (e.g. compare the positivity between the meta-
static cases [6,24,25,36,46,50-56] and non-metastatic
cases for the immunohistochemical antigen expression).
Conclusion
Our literature survey revealed that there were many
more cases of GP exceeding the submucosal layer than
were expected, and significant differences were found in
gender between GP within the submucosal layer and
exceeding the submucosal layer. Furthermore, our
immunohistochemical evaluation showed that both
epithelioid cells and normal pancreatic islet cells showed
strongly positive reactivity for progesterone receptors.
These immunohistochemical results support the follow-
ing two hypotheses. First, vertical growth of GP might
be affected by progesterone exposure. Second, the origin
of GP might be the pancreatic islet cells. However,
further investigation is required to confirm these
hypotheses.
Consent
Since the data of this study were extracted and sampled
from previous publications, written informed consent
for publication from patients does not exist with the
exception of our previous publication. As for our pre-
viously reported cases, written informed consent was
obtained from the patients for publication of this study
as well as any accompanying images. A copy of the writ-
ten consent is available for review by the Editor-in-Chief
of this journal. Furthermore, the anonymity of all
patients was strictly protected.
Abbreviation
GP: gangliocytic paraganglioma; NSE: neuron specific enolase; PP: pancreatic
polypeptide.
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